Venous Thromboembolism Clinical Trial
— JasonOfficial title:
Sulodexide (VESSEL®) for the Prevention of Recurrent Venous Thromboembolism in Elderly Patients After a First Episode of Venous Thrombembolism
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.
Status | Recruiting |
Enrollment | 1455 |
Est. completion date | December 2, 2023 |
Est. primary completion date | September 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 75 Years and older |
Eligibility | Inclusion Criteria: 1. Patients with a first event of proximal lower extremity DVT and / or PE, idiopathic or associated with weak or removed risk factors. 2. Patients aged =75 years at the time of enrolment 3. Patients with at least one of the known risk factors of bleeding (APPENDIX 1): 1. Hypertension 2. Renal failure 3. Thrombocytopenia 4. Diabetes 5. Antiplatelet therapy (ASA maximum 140 mg/die) 6. Frequent falls (>2 /years) 7. Nonsteroidal anti-inflammatory drug 8. Liver failure 9. Previous Stroke 10. Anemia 11. Poor anticoagulant control 12. Alcohol abuse 4. Patients of both sexes. 5. Patients who at the time of enrolment have already undergone a period of anticoagulant therapy (AT, with any medication) of at least 3 months and the therapy has not been suspended for more than 30 days. 6. Patients with no other AT indications. 7. Patients capable and able to provide informed consent Exclusion Criteria: 1. Patients aged <75 years at the time of the recruitment visit. 2. "Provoked" index event, which occurred: - Within 3 months of surgery or major trauma, - Bed Rest > 4 days, - Cast / immobility within 3 months. 3. Index event represented by severe PE, with life threatening risk or treated with thrombolytic therapy. 4. Index event represented by isolated distal DVT or superficial venous thrombosis. 5. Thrombotic event in sites other than the deep proximal veins of the lower limbs. 6. Anticoagulant therapy for less than 3 months at the time of enrolment. 7. Discontinuation of anticoagulant therapy for over thirty days at the time of enrolment 8. Recurrent episodes of DVT ± PE |
Country | Name | City | State |
---|---|---|---|
Italy | Corrado Lodigiani | Rozzano |
Lead Sponsor | Collaborator |
---|---|
Arianna Anticoagulazione Foundation |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy). | The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients | From date of enrollment until the date of first documented event assessed up to 12 months | |
Primary | Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety) | Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients | From date of enrollment until the date of first documented event assessed up to 12 months | |
Secondary | Number of and rate of thromboembolic events | Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients | From date of enrollment until the date of first documented event assessed up to 12 months | |
Secondary | Presence of severe post-thrombotic syndrome according to Villalta Score | Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score > of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome | 12 months | |
Secondary | Number and rate of non major bleeding complications | In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation | From date of enrollment until the date of first documented event assessed up to 12 months | |
Secondary | Number and rate of dead patients (overall mortality) | VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients | From date of enrollment until the date of first documented event assessed up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT02379806 -
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
|
Phase 3 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT01972243 -
Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
|
||
Completed |
NCT01976988 -
Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
|
Phase 3 |